Evidence map›Paper›PMID 29422418›Full record

ArticleEuropean urology focus2019

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Donna P Ankerst, Martin Goros, Scott A Tomlins, Dattatraya Patil, Ziding Feng, John T Wei, Martin G Sanda, Jonathan Gelfond, Ian M Thompson, Robin J Leach and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Donna P AnkerstDepartment of Urology, University of Texas Health at San Antonio, San Antonio, TX, USA; Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX, USA; Department of Mathematics, Technical University Munich, Garching, Germany. Electronic address: ankerst@tum.de.
Martin GorosDepartment of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX, USA.
Scott A TomlinsDepartments of Pathology and Urology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Dattatraya PatilDepartment of Urology, The Emory University School of Medicine, Atlanta, GA, USA.
Ziding FengDepartment of Urology, The Emory University School of Medicine, Atlanta, GA, USA.
John T WeiDepartments of Pathology and Urology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Martin G SandaDepartment of Urology, The Emory University School of Medicine, Atlanta, GA, USA.
Jonathan GelfondDepartment of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX, USA.
Ian M ThompsonCHRISTUS Medical Center Hospital, San Antonio, TX, USA.
Robin J LeachDepartment of Urology, University of Texas Health at San Antonio, San Antonio, TX, USA; Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX, USA.
Michael A LissDepartment of Urology, University of Texas Health at San Antonio, San Antonio, TX, USA. Electronic address: liss@uthscsa.edu.
Emory University · USThe University of Texas at San Antonio · USThe University of Texas Health Science Center at San Antonio · USChristus Health · USMichigan Center for Translational Pathology · USTechnical University of Munich · DEUniversity of Michigan–Ann Arbor · US

Funding

The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CAU01CA086402 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LEACH, ROBIN JEAN, THOMPSON, IAN M. · 2000 to 2018
$33.1M
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Elena Volpi · 2015 to 2026
$14.1M
PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchU01CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2019 to 2023
$5.4M
Biostatistics for Research in Genomics and CancerT32CA106209 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH G IBRAHIM, Naim Ur Rashid · 2004 to 2026
$4.8M
Bayesian Approaches to Model Selection for Survival DataR01GM070335 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IBRAHIM, JOSEPH G · 2003 to 2019
$4.0M
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3M
Dynamic, multi-cohort prediction modeling of prostate biopsy outcomeR01CA179115 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ANKERST, DONNA PAULER, VICKERS, ANDREW J · 2014 to 2018
$2.3M
Improving prostate biopsy efficiency: The finasteride challenge testR01CA138627 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HERNANDEZ, JAVIER, LEACH, ROBIN JEAN · 2010 to 2014
$2.1M
INFERENCE IN REGRESSION MODELS WITH MISSING COVARIATESR01CA074015 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IBRAHIM, JOSEPH G · 1997 to 2010
$1.7M
AHRQ HHS R03 HS024810NCI NIH HHS L30 CA199569NCI NIH HHS P20 CA165589NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA074015NCI NIH HHS R01 CA138627NCI NIH HHS R01 CA179115NCI NIH HHS T32 CA106209NCI NIH HHS U01 CA086402NCI NIH HHS U01 CA113913NCI NIH HHS U01 CA182883NCI NIH HHS U01 CA214170NCI NIH HHS U24 CA086368NIA NIH HHS P30 AG044271NIGMS NIH HHS R01 GM070335
6 · The paper itself

Abstract

backgroundThe Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) is a commonly used risk tool for predicting the outcome on biopsy based on the established risk factors.

objectiveTo determine whether incorporation of the novel urinary markers prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG (T2:ERG) into the PCPTRC improves its discrimination, accuracy, and clinical net benefit. DESIGN, SETTING, AND

participantsSince PCA3 and T2:ERG were not measured as part of the PCPTRC, a Bayesian modeling approach was used to combine data where the markers were measured in a Michigan cohort with the PCPTRC as prior probabilities to form an updated PCPTRC. This update was compared to the existing PCPTRC on an independent Early Detection Research Network cohort in terms of discrimination, calibration, and decision curve analysis. RESULTS AND LIMITATIONS: Among the 1225 Michigan biopsies, 57.7%, 24.0%, and 18.3% were negative, with low- and high-grade (Gleason grade≥7) prostate cancer, respectively. Evaluated on the Early Detection Research Network validation set comprising 854 biopsies, areas under the curve (95% confidence interval) for predicting high-grade cancer in the 854 biopsies comprising the validation set were 70.0% (66.0-74.0%), 76.4% (72.8-80.0%), and 77.1% (73.6-80.6%) for the PCPTRC alone, with PCA3 added, and PCA3 and T2:ERG added, respectively. Net benefit was improved for the updated PCPTRC, while calibration was not. Limitations are that the updated PCPTRC is based on two different cohorts, the PCPT and Michigan, and that 20% of the validation set came from the Michigan center. More validation is required; hence, the updated risk tool is posted online.

conclusionsIncorporation of PCA3 into the PCPTRC improved validation on an independent cohort, whereas T2:ERG offered negligible utility in addition to PCA3. PATIENT SUMMARY: After passing external validation, prostate cancer antigen 3 has been added to the online Prostate Cancer Prevention Trial Risk Calculator for use by patients in deciding whether to proceed to biopsy. TMPRSS2:ERG did not improve prediction on the external validation set, but is included for further validation.

Indexed as

AdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorEarly Detection of CancerHumansMaleMiddle AgedNeoplasm GradingOncogene Proteins, FusionProstatic NeoplasmsRisk AssessmentSerine EndopeptidasesTranscriptional Regulator ERGAntigens, NeoplasmBiomarkers, TumorERG protein, humanOncogene Proteins, Fusionprostate cancer antigen 3, humanSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERGPCA3Prostate cancerProstate-specific antigenT2:ERG

Identifiers

PMID29422418
PMCPMC6077104
OpenAlexW2787052995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.